Inmune Bio, Inc.(INMB)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Inmune Bio, Inc. (INMB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INMB at 9.7/100 on a 32-signal composite quality model, placing it at rank #2,913 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of INMB by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, AQR CAPITAL MANAGEMENT, BlackRock, based on the most recent SEC filings. INMB trades on the Nasdaq exchange and files with the SEC under CIK 1711754. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INMB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Inmune Bio, Inc. directly from SEC EDGAR.
AI Quality Score
9.7/100
AI Rank
#2,913
Net Income
$-1.3M
INMB key financials by period
Inmune Bio, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$50.0K
$-45.9M
—
FY 2024
10-K
$14.0K
$-42.1M
—
FY 2023
10-K
$155.0K
$-30.0M
—
FY 2022
10-K
$374.0K
$-27.3M
—
FY 2021
10-K
$181.0K
$-30.3M
—
FY 2020
10-K
$11.0K
$-12.1M
—
Institutions holding INMB
Institutional investors reporting a position in Inmune Bio, Inc. on SEC Form 13F.
